menu
    • menu
    [{"orgOrder":0,"company":"Polifarma","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Darbepoetin alfa","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Polifarma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polifarma \/ Polifarma","highestDevelopmentStatusID":"12","companyTruncated":"Polifarma \/ Polifarma"},{"orgOrder":0,"company":"Polifarma","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"TURKEY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polifarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polifarma \/ Alvotech","highestDevelopmentStatusID":"10","companyTruncated":"Polifarma \/ Alvotech"}]

    Find Clinical Drug Pipeline Developments & Deals by Polifarma

    Menu

    Polifarma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polifarma

                            Turkey arrow
                            Antibody Engineering
                            Not Confirmed

                            Polifarma

                            Turkey arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alvotech Enters Into Commercialization Agreement With Polifarma For Proposed Biosimilar to Eylea® (aflibercep...

                            Details : According to the agreement, Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization of AVT06, a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept).

                            Brand Name : AVT06

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 10, 2023

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polifarma

                            Turkey arrow
                            Antibody Engineering
                            Not Confirmed

                            Polifarma

                            Turkey arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Recipient : Dong-A ST Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880

                            Details : According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.

                            Brand Name : DA-3880

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : Darbepoetin alfa

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Recipient : Dong-A ST Co., Ltd.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth